These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 35135481

  • 1. Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE.
    Fishbane S, Ford M, Fukagawa M, McCafferty K, Rastogi A, Spinowitz B, Staroselskiy K, Vishnevskiy K, Lisovskaja V, Al-Shurbaji A, Guzman N, Bhandari S.
    BMC Nephrol; 2022 Feb 08; 23(1):59. PubMed ID: 35135481
    [Abstract] [Full Text] [Related]

  • 2. DIALIZE China: A Phase IIIb, Randomized, Placebo-Controlled Study to Reduce Predialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese Patients.
    Ni Z, Lu R, Xu X, Bian X, Zhou Z, Yang J, Luo Q, Chen M, Chen C, Sun X, Yu L, He Q, Jiang H, Yuan W, Li Y, Zhou R, Wang J, Zhang X, Zuo L, Meng X, Chang Z, Zhao J, Wessman P, Xiang P, DIALIZE China Study Group.
    Clin Ther; 2023 Jul 08; 45(7):633-642. PubMed ID: 37385905
    [Abstract] [Full Text] [Related]

  • 3. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
    Fishbane S, Ford M, Fukagawa M, McCafferty K, Rastogi A, Spinowitz B, Staroselskiy K, Vishnevskiy K, Lisovskaja V, Al-Shurbaji A, Guzman N, Bhandari S.
    J Am Soc Nephrol; 2019 Sep 08; 30(9):1723-1733. PubMed ID: 31201218
    [Abstract] [Full Text] [Related]

  • 4. Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE).
    Peacock WF, Rafique Z, Vishnevskiy K, Michelson E, Vishneva E, Zvereva T, Nahra R, Li D, Miller J.
    Acad Emerg Med; 2020 Jun 08; 27(6):475-486. PubMed ID: 32149451
    [Abstract] [Full Text] [Related]

  • 5. Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.
    Zhang Y, Xu R, Wang F, Liu Y, Xu J, Zhao N, Cheng F, Long L, Jia J, Lin S.
    Cardiovasc Drugs Ther; 2021 Oct 08; 35(5):1057-1066. PubMed ID: 33459923
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. HARMONIZE Asia: A Phase III Randomized Study to Investigate the Efficacy and Safety of Sodium Zirconium Cyclosilicate in Patients with Hyperkalemia in China.
    Liang X, Lu W, Yu X, Cheng H, He Q, Peng Q, Ni Z, Long G, Wang L, Chen W, Li R, Zhao J, Zhang Y, Lisovskaja V, Tang Z.
    Clin Ther; 2024 Sep 08; 46(9):702-710. PubMed ID: 39112102
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the effect of sodium zirconium cyclosilicate on arrhythmia-related cardiovascular outcomes in patients receiving chronic haemodialysis with hyperkalaemia: protocol for the multicentre, randomised, controlled DIALIZE-Outcomes study.
    Fishbane S, Jadoul M, Dember L, Kovesdy CP, Al-Shurbaji A, Lisovskaja V, Sekar P, Katona B, Guzman N, Herzog C.
    BMJ Open; 2023 May 25; 13(5):e071309. PubMed ID: 37230521
    [Abstract] [Full Text] [Related]

  • 9. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study.
    Roger SD, Lavin PT, Lerma EV, McCullough PA, Butler J, Spinowitz BS, von Haehling S, Kosiborod M, Zhao J, Fishbane S, Packham DK.
    Nephrol Dial Transplant; 2021 Jan 01; 36(1):137-150. PubMed ID: 32030422
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level ≥ 5.5 mmol/L: pooled analysis from two phase 3 trials.
    Amin AN, Menoyo J, Singh B, Kim CS.
    BMC Nephrol; 2019 Dec 02; 20(1):440. PubMed ID: 31791288
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE.
    Roger SD, Spinowitz BS, Lerma EV, Singh B, Packham DK, Al-Shurbaji A, Kosiborod M.
    Am J Nephrol; 2019 Dec 02; 50(6):473-480. PubMed ID: 31658466
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Population Pharmacodynamic Dose-Response Analysis of Serum Potassium Following Dosing with Sodium Zirconium Cyclosilicate.
    Penland RC, Åstrand M, Boulton DW, Någård M.
    Clin Pharmacokinet; 2024 Apr 02; 63(4):551-560. PubMed ID: 38504082
    [Abstract] [Full Text] [Related]

  • 15. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.
    Spinowitz BS, Fishbane S, Pergola PE, Roger SD, Lerma EV, Butler J, von Haehling S, Adler SH, Zhao J, Singh B, Lavin PT, McCullough PA, Kosiborod M, Packham DK, ZS-005 Study Investigators.
    Clin J Am Soc Nephrol; 2019 Jun 07; 14(6):798-809. PubMed ID: 31110051
    [Abstract] [Full Text] [Related]

  • 16. Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials.
    Roger SD, Spinowitz BS, Lerma EV, Fishbane S, Ash SR, Martins JG, Quinn CM, Packham DK.
    Nephrol Dial Transplant; 2021 Apr 26; 36(5):871-883. PubMed ID: 32588050
    [Abstract] [Full Text] [Related]

  • 17. Plant-based diet in hyperkalemic chronic kidney disease patients receiving sodium zirconium cyclosilicate: a feasibility clinical trial.
    Avesani CM, Heimbürger O, Rubin C, Sallstrom T, Fáxen-Irving G, Lindholm B, Stenvinkel P.
    Am J Clin Nutr; 2024 Sep 26; 120(3):719-726. PubMed ID: 39032787
    [Abstract] [Full Text] [Related]

  • 18. Effect of Sodium Zirconium Cyclosilicate on Serum Potassium and Bicarbonate in Patients with Hyperkalemia and Metabolic Acidosis Associated with Chronic Kidney Disease: Rationale and Design of the NEUTRALIZE Study.
    Ash SR, Batlle D, Kendrick J, Oluwatosin Y, Pottorf W, Brahmbhatt Y, Guerrieri E, Fried L.
    Nephron; 2022 Sep 26; 146(6):599-609. PubMed ID: 35462371
    [Abstract] [Full Text] [Related]

  • 19. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
    Takkar C, Nassar T, Qunibi W.
    Expert Opin Pharmacother; 2021 Jan 26; 22(1):19-28. PubMed ID: 32892634
    [Abstract] [Full Text] [Related]

  • 20. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
    Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B.
    JAMA; 2014 Dec 03; 312(21):2223-33. PubMed ID: 25402495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.